Medical research company
Medical Discoveries
Turning the notes doctors already write into structured evidence for research.
- Bob’s role
- Co-founder and board chair
- CEO & Co-founder
- Dr. Christopher Voss
- Status
- Development stage
Why it matters to him
This is his AI-for-good work, outside the children's safety effort. “We are using AI to improve the quality of human existence…” he says, and he credits the idea to research methods his son, a physician-scientist, uses.
What it is
Medical Discoveries describes itself carefully, and this page keeps to its words: “Medical Discoveries is developing a clinical evidence platform to support research and hospital analytics. We aim to turn available clinical documentation into structured information that can help researchers investigate clinically meaningful questions. Specific capabilities, integration, staffing, timing and delivery depend on project scope and readiness.”
In plainer terms: hospitals hold an enormous amount of knowledge in the free-text notes that doctors and surgeons write every day. The electronic record stores those notes, but it does not turn them into data that can be studied at scale. Medical Discoveries is building the layer that would. Inside a hospital, structured data could support medication-safety checks, accreditation tracking and clearer summaries of a patient’s course. For research, data would have identifiers removed under the hospital’s privacy rules, with any re-identification key kept inside the hospital. The company’s own line: “Better clinical data. Stronger evidence. New possibilities for care.”
How it works
The idea began with a method called target trial emulation, which brings the design discipline of a randomized trial to observational data: the protocol comes first, then the data. Bob credits the inspiration to research methods his son, Dr. David Leaf, a physician-scientist, uses. That research is independent of the company and is not evidence for it.
The company states its own limits plainly: “Observational analyses remain subject to confounding, bias and data limitations; they do not by themselves establish randomized-trial equivalence or guarantee regulatory acceptance.” On data, identifiable information is meant to stay inside the hospital. Research access is being developed project by project, with the rules for de-identification, access and output review defined before any access begins.
Where it stands
Development stage. The company lists its offerings as available for scoping or as concepts under development, and says so directly: scoping is exploratory and does not indicate a deployed service. Bob has described the first task as one hospital, its notes turned into structured, searchable fields. This page makes no claims about clients, outcomes or results.
The CEO and co-founder is Dr. Christopher Voss, a physician.
Bob’s part
Bob co-founded the company and chairs its board. He is not a physician. He is a dentist who spent decades building large systems in healthcare and insurance. “I have started many companies; this seems to be the strongest,” he wrote in September 2026.
This company is at an early stage. Its products are still being developed. Nothing here is medical advice or a claim about results.